Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups
暂无分享,去创建一个
F. Saad | M. Graefen | A. Briganti | S. Shariat | P. Karakiewicz | F. Chun | M. Wenzel | V. Mirone | Z. Tian | D. Tilki | L. Nocera | C. Würnschimmel | Claudia Colla' Ruvolo
[1] K. Chi,et al. Apalutamide for metastatic, castration‐sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double‐blind, placebo‐controlled phase 3 TITAN study , 2020, International journal of urology : official journal of the Japanese Urological Association.
[2] Life expectancy at birth, by sex, 2000 and 2017 (or nearest year) , 2020, Health at a Glance: Latin America and the Caribbean 2020.
[3] F. Saad,et al. The Impact of Race and Age on Distribution of Metastases in Patients with Prostate Cancer. , 2020, The Journal of urology.
[4] M. Terris,et al. Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. , 2019, JAMA oncology.
[5] N. Agarwal,et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. , 2019, The New England journal of medicine.
[6] Edmund Chiong,et al. The incidence, mortality, and risk factors of prostate cancer in Asian men , 2018, Prostate international.
[7] R. Cress,et al. Changing Incidence of Metastatic Prostate Cancer by Race and Age, 1988-2015. , 2019, European urology focus.
[8] F. Saad,et al. Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database. , 2019, European urology focus.
[9] D. Moreira,et al. Prostate cancer disparities in Hispanics by country of origin: a nationwide population-based analysis , 2018, Prostate Cancer and Prostatic Diseases.
[10] J. Brooks,et al. Trends in incidence and 5‐year mortality in men with newly diagnosed, metastatic prostate cancer—A population‐based analysis of 2 national cohorts , 2018, Cancer.
[11] S. Eggener,et al. African-American Prostate Cancer Disparities , 2017, Current Urology Reports.
[12] M. Carducci,et al. Impact of ethnicity on the outcome of men with metastatic, hormone‐sensitive prostate cancer , 2017, Cancer.
[13] T. Choueiri,et al. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] F. Saad,et al. Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study , 2017, International Urology and Nephrology.
[15] David F Jarrard,et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.
[16] K. Attwood,et al. Androgen Receptor Mutations and Polymorphisms in African American Prostate Cancer , 2014, International journal of biological sciences.
[17] R. deVere White,et al. No improvement noted in overall or cause‐specific survival for men presenting with metastatic prostate cancer over a 20‐year period , 2014, Cancer.
[18] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[19] Pierre I Karakiewicz,et al. A population‐based competing‐risks analysis of the survival of patients treated with radical cystectomy for bladder cancer , 2011, Cancer.
[20] Cancer Facts & Figures 2021 , 2010 .
[21] B. Hollenbeck,et al. Five‐year survival after surgical treatment for kidney cancer , 2007, Cancer.
[22] T. Namiki,et al. Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men , 2006, BJU international.
[23] Å. Borg,et al. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk , 1999, British Journal of Cancer.